Donor T-cell treatment after transplant for high-risk AML and MDS
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 trial studies an advanced form of donated immune cells given after a stem cell transplant to help prevent leukemia coming back. It mainly looks at safety and whether the treatment can work in people with very high-risk AML or MDS who have not relapsed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 6 months to 80 years
- You are planning or have had an allogeneic stem cell transplant (donor transplant)
- Your AML or MDS is “high-risk,” and you have not had a relapse in the blood/bone marrow
- Your strength/function score is at least 50 (Karnofsky/Lansky)
- T-cell “chimerism” levels are high (donor T cells make up enough of your body’s T cells)
- You must be able to give informed consent (or your parent/guardian can)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of immunotherapy using special white blood cells (T-cells) that are trained to find and attack cancer cells. It is for children and young adults with high-risk solid tumors that have not gone away or have come back after standard treatment.
This early-phase trial tests an immune “T cell” therapy made to recognize a specific leukemia target. It is for people whose acute leukemia has come back (relapsed) or did not fully respond after receiving a donor stem cell transplant.
This trial tests whether giving specially engineered donor T-cells after a stem cell transplant can help treat certain blood cancers like AML or MDS. The study is for people receiving a donor stem cell transplant for the first time.
This trial tests an injection of donor-derived immune cells (called RC1012) to lower the chance of AML coming back after an allogeneic stem cell transplant. It is aimed at people at higher risk of relapse once the transplant is completed.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
This trial tests specially engineered donor T cells (TSC-100 or TSC-101) given after a stem cell transplant to help prevent cancer relapse in people with AML, MDS, or ALL. It is for patients who have a specific genetic marker (HA-1 or HA-2) and a matched donor.
Hear when a new Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.